Ms. Celia Economides reports

AURINIA ANNOUNCES PUBLIC OFFERING OF COMMON SHARES

Aurinia Pharmaceuticals Inc. has commenced a registered underwritten public offering of its common shares.

Leerink Partners LLC and Cantor Fitzgerald & Co. are acting as joint bookrunning managers for the offering. The company will grant the underwriters an option exercisable, in whole or in part, in the sole discretion of the underwriters, to purchase additional shares for a period of up to 30 days.

The offering is subject to market conditions, as well as Nasdaq and Toronto Stock Exchange approvals, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. For the purposes of the TSX approval, the company intends to rely on the exemption set forth in Section 602.1 of the TSX company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq. The company intends to use the net proceeds of the offering for research and development activities, including phase 3 clinical trial activities for lupus nephritis, and working capital purposes.

The offering is being made pursuant to a United States registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission on Nov. 5, 2015, and the company's existing Canadian short form base shelf prospectus dated Oct. 16, 2015. The prospectus supplements relating to the offering will be filed with the securities commissions in the provinces of British Columbia, Alberta and Ontario in Canada, and with the SEC in the United States. The offering documents will contain important detailed information about the securities being offered. Before you invest, you should read the offering documents and the other documents the company has filed for more complete information about the company and the offering. Copies of the offering documents will be available free by visiting the company's profile on the SEDAR website maintained by the Canadian Securities Administrators, or the SEC website, as applicable. Alternatively, copies of the prospectus supplement will be available upon request by contacting Leerink Partners LLC.

About Aurinia Pharmaceuticals Inc.

Aurinia is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug for the treatment of lupus nephritis.